Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.

Article Details

Citation
Copy to clipboard

Orr RM

Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.

Curr Opin Mol Ther. 2001 Jun;3(3):288-94.

PubMed ID
11497353 [ View in PubMed
]
Abstract

Fomivirsen (ISIS-2922, Vitravene) is an antisense 21 mer phosphorothioate oligonucleotide with sequence complementarity to the coding region of the major immediate-early gene of human cytomegalovirus (CMV). Developed by Isis Pharmaceuticals Inc, fomivirsen is the first antisense oligonucleotide to receive approval for licensing and is marketed by Novartis' CIBA Vision. Fomivirsen is administered by intravitreal injection to AIDS patients for the treatment of CMV-induced retinitis. In August 1998, the FDA approved the marketing of Vitravene for the local treatment of CMV retinitis [296420], [296780], and both European and Brazilian registration approval followed in the summer of 1999 [335238].

DrugBank Data that Cites this Article

Drugs